You make a good point. The genetic data may very well provide clues about how to modify the molecule to get the "normal" responders to achieve the same level of response as the "super responders".
Or it may indicate that there is another pathway involved in the super responders that is not activated in the normal responders.
There is no way to know in advance where that genetic analysis will lead.
Right now the limited data suggests that one size of 2-73 does fit all. That is it looks like everyone has a positive response to it. Some pts respond much more than others.
For the present, that 2-73 gets a positive response from all or the large majority of pts is the bottom line that will get FDA approval I think.
If later on it is shown that there are subgroups that respond even better then those groups can be specifically targeted. That doesn't mean that the general use will be eliminated. (I hope)
News 
Market Data 
Discover 
